Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual MeetingAbstracts 1106, 183: Nivolumab and ipilimumab for relapsed/refractory hematologic cancers
1:50 minutes.
TRANSCRIPTION:
DR FLOWERS: So in this trial, Catherine Diefenbach presented data from the combination of nivolumab and brentuximab in a Phase I trial with dose escalation, giving nivolumab at 3 mg/kg in all cohorts and then dose escalating the brentuximab, first given at 1.2 mg/kg and then given at 1.8 mg/kg. In this Phase I trial, what was seen is, if you look at the safety of the regimen, that it was allowed to progress from that first cohort on to the second cohort. The toxicities that were seen were at least 1 dose-limiting toxicity consisting of pneumonitis and dyspnea. And that patient was one who had received a prior transplant, and perhaps that may have predisposed to some of those toxicities. The patient did make a full recovery after those toxicities. And no other DLTs were seen in this cohort. I think that at this point, many more patients are going to need to be treated, particularly in the Phase II setting, before we can fully appreciate what the toxicities of this combination are. But these are at least meaningful enough to move forward on the basis of toxicity. What we also saw in terms of the efficacy — again, in small numbers of patients — that 100% of those patients responded, with a 66% complete response rate. So this again looks like another promising combination that we will need to add into the armamentarium as we try to consider what combinations of therapy versus sequences of single-agent therapies are options. |